PREFER BL | PREFER EOS | Change % | p Value | Control BL | Control EOS | Change % | p Value | |
---|---|---|---|---|---|---|---|---|
Number of patients | 36 | 31 | 36 | 33 | ||||
ACEI | 21 (58) | 21 (68) | +10 | 0.42 | 16 (44) | 14 (42) | −2 | 0.87 |
ARB | 11 (31) | 9 (29) | −2 | 0.89 | 17 (47) | 17 (52) | +5 | 0.72 |
RAS blockade | 31 (86) | 29 (94) | +8 | 0.32 | 33 (92) | 31 (94) | +2 | 0.72 |
BB | 29 (81) | 24 (77) | −4 | 0.75 | 31 (86) | 28 (85) | −1 | 0.88 |
MRA | 10 (28) | 15 (48) | +20 | 0.08 | 13 (36) | 13 (39) | +3 | 0.785 |
Loop diuretics | 32 (89) | 27 (87) | −2 | 0.82 | 34 (94) | 32 (97) | +3 | 0.61 |
Digitalis | 8 (22) | 8 (26) | +4 | 0.95 | 5 (14) | 6 (18) | +4 | 0.63 |
Data are given as n (%). The % change between BL and the EOS is shown.
ACEI, ACE inhibitors; ARB, angiotensin receptor blocker; BB, β receptor blocker; BL, baseline; CHF, chronic heart failure; EOS, end of study; MRA, mineralocorticoid receptor antagonist; PREFER, Palliative advanced homecaRE and heart FailurE caRe; RAS, renin-angiotensin-system.